{
    "nctId": "NCT05911958",
    "briefTitle": "A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer",
    "officialTitle": "Phase II Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "HER2 Low Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 66,
    "primaryOutcomeMeasure": "Objective Response Rate (ORR) Tumours (RECIST) v1.1",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients aged 18 to 70 years old (inclusive);\n2. Treatment-naive patients with clinically confirmed T2-T3, any nodal status and M0;\n3. HR-positive, HER2 low expression, the expression of Ki-67 exceed 14% invasive breast cancer confirmed by histology or cytology;\n4. ECOG performance status of 0-1;\n5. Normal organ and bone marrow function;\n6. Patients of childbearing age must consent to use highly effective contraception for 7 months from the start of study screening until the last study medication and agree not to breastfeeding;\n7. Patients voluntarily joined the study and signed informed consent;\n\nExclusion Criteria:\n\n1. Patients have evidence of metastatic breast cancer, or inflammatory breast cancer;\n2. Patients previously received antineoplastic therapy or radiotherapy for any malignancy, excluding cured malignancies such as cervical carcinoma in situ, basal cell carcinoma, or squamous carcinoma;\n3. Patients received any other anti-tumor therapy at the same time, including endocrine therapy, bisphosphonates or immunotherapy;\n4. Patients have major surgical procedures unrelated to breast cancer within 4 weeks before the first medication, or not fully recovered from surgical procedures;\n5. Clinically significant pulmonary or cardiovascular disease;\n6. Failure to swallow, chronic diarrhea, intestinal obstruction, or presence of other factors affecting drug administration and absorption;\n7. Known to be allergic to any study drug or any of its excipients;\n8. History of immunodeficiency, including HIV-positive, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation;\n9. Pregnant and lactating women;\n10. Patients with serious concomitant diseases or other comorbidities that will interfere with the planned treatment, or any other condition that is not suitable for participation assessed by investigator.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}